|
TW467902B
(en)
*
|
1996-07-31 |
2001-12-11 |
Bristol Myers Squibb Co |
Diphenyl heterocycles as potassium channel modulators
|
|
PT1056754E
(pt)
*
|
1998-01-29 |
2004-03-31 |
Bristol Myers Squibb Co |
Derivados fosfatados de 1,3,4-oxadiazolona de diarilo
|
|
AU736599B2
(en)
*
|
1998-01-29 |
2001-08-02 |
Bristol-Myers Squibb Company |
Amino acid derivatives of diaryl 1,3,4-oxadiazolone
|
|
AU735704B2
(en)
*
|
1998-01-29 |
2001-07-12 |
Bristol-Myers Squibb Company |
Derivatives of 1,3,4-oxadiazolone
|
|
AU736712B2
(en)
*
|
1998-01-29 |
2001-08-02 |
Bristol-Myers Squibb Company |
Benzoate derivatives of diaryl 1,3,4-oxadiazolone
|
|
DE19816882A1
(de)
*
|
1998-04-17 |
1999-10-21 |
Boehringer Ingelheim Pharma |
Triazolone mit neuroprotektiver Wirkung
|
|
US6911462B2
(en)
*
|
1998-05-22 |
2005-06-28 |
Avanir Pharmaceuticals |
Benzimidazole compounds for regulating IgE
|
|
US6919366B2
(en)
*
|
1998-05-22 |
2005-07-19 |
Avanir Pharmaceuticals |
Benzimidazole derivatives as modulators of IgE
|
|
SE9802937D0
(sv)
*
|
1998-09-01 |
1998-09-01 |
Astra Pharma Prod |
Novel compounds
|
|
US6632836B1
(en)
|
1998-10-30 |
2003-10-14 |
Merck & Co., Inc. |
Carbocyclic potassium channel inhibitors
|
|
US6303637B1
(en)
*
|
1998-10-30 |
2001-10-16 |
Merck & Co., Inc. |
Heterocyclic potassium channel inhibitors
|
|
US6194458B1
(en)
|
1998-10-30 |
2001-02-27 |
Merck & Co., Inc. |
Benzamide potassium channel inhibitors
|
|
US6297241B1
(en)
|
1999-01-29 |
2001-10-02 |
Bristol-Myers Squibb Company |
Carbamate derivatives of diaryl 1,3,4-oxadiazolone
|
|
US6162817A
(en)
*
|
1999-01-29 |
2000-12-19 |
Bristol-Myers Squibb Company |
Carbamate derivatives of diaryl 1,3,4-oxadiazolone
|
|
GB9915414D0
(en)
*
|
1999-07-01 |
1999-09-01 |
Glaxo Group Ltd |
Medical use
|
|
US7018979B1
(en)
|
2000-01-26 |
2006-03-28 |
Cedars-Sinai Medical Center |
Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor
|
|
US20050153940A1
(en)
*
|
2000-01-26 |
2005-07-14 |
Cedars-Sinai Medical Center |
Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor
|
|
GB2361003A
(en)
*
|
2000-04-07 |
2001-10-10 |
Astrazeneca Ab |
Novel compounds
|
|
HUP0303559A3
(en)
*
|
2000-10-13 |
2006-02-28 |
Bristol Myers Squibb Co |
Selective maxi-k-potassium channel openers functional under conditions of high intracellular calcium concentration and uses thereof
|
|
DE10056344A1
(de)
*
|
2000-11-14 |
2002-05-16 |
Degussa |
n-Propylethoxysiloxane, Verfahren zu deren Herstellung und deren Verwendung
|
|
DE10058461A1
(de)
*
|
2000-11-24 |
2002-09-19 |
Bayer Ag |
Substituierte Cyclohexanderivate und ihre Verwendung
|
|
MXPA03007397A
(es)
|
2001-02-20 |
2003-12-04 |
Bristol Myers Squibb Co |
Moduladores de canales de potasio kcnq y uso de los mismos en tratamiento de migrana y enfermedades mecanicamente relacionadas.
|
|
ES2291455T3
(es)
*
|
2001-03-12 |
2008-03-01 |
Avanir Pharmaceuticals |
Compuestos de bencimidazol para modular ige e inhibir la proliferacion celular.
|
|
CN100540538C
(zh)
*
|
2001-04-16 |
2009-09-16 |
田边三菱制药株式会社 |
高传导率钙-活化k通道开启剂
|
|
US7022480B1
(en)
|
2001-10-11 |
2006-04-04 |
The Regents Of The University Of California |
Exons of the hSKCa3/KCNN3 gene
|
|
US7211561B2
(en)
*
|
2001-10-12 |
2007-05-01 |
Cedars-Sinai Medical Center |
Method for inducing selective cell death of malignant cells by activation of calcium-activated potassium channels (KCa)
|
|
US6613786B2
(en)
|
2001-11-02 |
2003-09-02 |
Bristol-Myers Squibb Company |
Thiophenyl triazol-3-one derivatives as smooth muscle relaxants
|
|
US7846671B2
(en)
*
|
2002-01-28 |
2010-12-07 |
Bristol-Myers Squibb Company |
Methods of screening for agents that modulate the interaction of RGS and Gαq and urinary incontinence
|
|
TW200304820A
(en)
*
|
2002-03-25 |
2003-10-16 |
Avanir Pharmaceuticals |
Use of benzimidazole analogs in the treatment of cell proliferation
|
|
TWI276631B
(en)
*
|
2002-09-12 |
2007-03-21 |
Avanir Pharmaceuticals |
Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
|
|
WO2004024655A2
(en)
|
2002-09-12 |
2004-03-25 |
Avanir Pharmaceuticals |
Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation
|
|
TWI271402B
(en)
*
|
2002-10-15 |
2007-01-21 |
Tanabe Seiyaku Co |
Large conductance calcium-activated K channel opener
|
|
TW200505441A
(en)
|
2003-03-24 |
2005-02-16 |
Hoffmann La Roche |
Non-nucleoside reverse transcriptase inhibitorsⅠ
|
|
MXJL05000041A
(es)
*
|
2003-04-10 |
2005-12-22 |
Avanir Pharmaceuticals |
Compuestos de imidazol para el tratamiento de padecimientos alergicos e hiperproliferativos.
|
|
GB0315111D0
(en)
|
2003-06-27 |
2003-07-30 |
Cancer Rec Tech Ltd |
Substituted 5-membered ring compounds and their use
|
|
AU2004263190A1
(en)
*
|
2003-08-08 |
2005-02-17 |
Avanir Pharmaceuticals |
Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
|
|
WO2005097758A1
(en)
*
|
2004-03-26 |
2005-10-20 |
Amphora Discovery Corporation |
Certain triazole-based compounds, compositions, and uses thereof
|
|
US7459457B2
(en)
*
|
2004-04-13 |
2008-12-02 |
Icagen, Inc. |
Polycyclic pyridines as potassium ion channel modulators
|
|
US8293778B2
(en)
|
2004-07-27 |
2012-10-23 |
Roche Palo Alto Llc |
Heterocyclic antiviral compounds
|
|
CA2574308C
(en)
*
|
2004-07-27 |
2014-03-25 |
F. Hoffmann-La Roche Ag |
Benzyltriazolone compounds as non-nucleoside reverse transcriptase inhibitors
|
|
EP1815206B1
(en)
*
|
2004-10-13 |
2016-04-06 |
PTC Therapeutics, Inc. |
Compounds for nonsense suppression, and methods for their use
|
|
EP2298748B1
(en)
*
|
2004-11-18 |
2016-07-20 |
Synta Pharmaceuticals Corp. |
Triazole compounds that modulate HSP90 activity
|
|
EP1850852A4
(en)
*
|
2005-02-22 |
2009-11-18 |
Cedars Sinai Medical Center |
USE OF SILDENAFIL, VARDENAFIL AND OTHER 5-PHOSPHODIESTERASE INHIBITORS TO INCREASE THE PERMEABILITY OF THE ABNORMAL BLOOD-BRAIN DISEASE
|
|
US7608635B2
(en)
|
2005-08-12 |
2009-10-27 |
Synta Pharmaceuticals Corp. |
Pyrazole compounds that modulate HSP90 activity
|
|
EP1928846B1
(en)
*
|
2005-08-18 |
2014-06-04 |
Synta Pharmaceuticals Corp. |
Triazole compounds that modulate hsp90 activity
|
|
CA2618724A1
(en)
|
2005-08-18 |
2007-02-22 |
Synta Pharmaceuticals Corp. |
Imidazole compounds that modulate hsp90 activity
|
|
DE102006024024A1
(de)
*
|
2006-05-23 |
2007-11-29 |
Bayer Healthcare Aktiengesellschaft |
Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
|
|
TWI490212B
(zh)
*
|
2006-05-25 |
2015-07-01 |
Synta Pharmaceuticals Corp |
調節ｈｓｐ９０活性之三唑化合物
|
|
CA2653329C
(en)
|
2006-05-25 |
2018-01-16 |
Synta Pharmaceuticals Corp. |
Triazole compounds that modulate hsp90 activity
|
|
TW200804313A
(en)
|
2006-05-25 |
2008-01-16 |
Synta Pharmaceuticals Corp |
Triazole compounds that modulate HSP90 activity
|
|
US20080027047A1
(en)
*
|
2006-05-25 |
2008-01-31 |
Weiwen Ying |
Compounds that modulate HSP90 activity and methods for identifying same
|
|
WO2008087177A1
(en)
*
|
2007-01-18 |
2008-07-24 |
Neurosearch A/S |
Novel semicarbazide and carbonylhydrazide derivatives useful as potassium channel modulators
|
|
KR20090127178A
(ko)
|
2007-03-29 |
2009-12-09 |
에프. 호프만-라 로슈 아게 |
비뉴클레오시드 역전사 효소 억제제
|
|
WO2008135447A1
(en)
*
|
2007-05-03 |
2008-11-13 |
Neurosearch A/S |
Acetamide derivatives as potassium channel modulators
|
|
EP2280948A1
(en)
|
2008-04-09 |
2011-02-09 |
Mitsubishi Tanabe Pharma Corporation |
Pyrimidine, pyridine and triazine derivatives as maxi-k channel openers.
|
|
US20090281089A1
(en)
*
|
2008-04-11 |
2009-11-12 |
Genentech, Inc. |
Pyridyl inhibitors of hedgehog signalling
|
|
PE20091953A1
(es)
*
|
2008-05-08 |
2010-01-09 |
Du Pont |
Azoles sustituidos como fungicidas
|
|
EP2560640A1
(en)
|
2010-04-19 |
2013-02-27 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
|
|
WO2013067162A1
(en)
|
2011-11-02 |
2013-05-10 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
|
|
JP2014534228A
(ja)
|
2011-11-02 |
2014-12-18 |
シンタ ファーマシューティカルズ コーポレーション |
白金含有剤とｈｓｐ９０阻害剤の組合せ療法
|
|
EP2780010A1
(en)
|
2011-11-14 |
2014-09-24 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitors with braf inhibitors
|
|
EP2822931B1
(en)
|
2012-03-09 |
2017-05-03 |
Inception 2, Inc. |
Triazolone compounds and uses thereof
|
|
ES2660249T3
(es)
|
2012-12-20 |
2018-03-21 |
Inception 2, Inc. |
Compuestos de tipo triazolona y sus usos
|
|
JP2016529311A
(ja)
|
2013-09-06 |
2016-09-23 |
インセプション ２、 インコーポレイテッド |
トリアゾロン化合物類及びそれらの使用
|
|
WO2016033285A1
(en)
|
2014-08-29 |
2016-03-03 |
E. I. Du Pont De Nemours And Company |
Herbicidal triazoles
|
|
CN104710379B
(zh)
*
|
2015-03-09 |
2017-01-18 |
华南理工大学 |
一种bms‑191011的合成方法
|
|
US12194026B2
(en)
*
|
2018-10-26 |
2025-01-14 |
University Of South Florida |
Drug for treating tinnitus
|
|
CN114746151A
(zh)
*
|
2019-10-07 |
2022-07-12 |
D·E·萧尔研究有限责任公司 |
作为Kv1.3钾Shaker通道阻断剂的芳基杂环化合物
|
|
BR112022006242A2
(pt)
*
|
2019-10-07 |
2022-06-21 |
De Shaw Res Llc |
Compostos aromáticos de arilmetileno como bloqueadores de canal do agitador de potássio kv1,3
|
|
CN115504940A
(zh)
*
|
2021-06-23 |
2022-12-23 |
中国科学院上海药物研究所 |
一种酰胺类化合物、其制备方法和制药用途
|